Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137575

Published: 2020

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95)

Blood (2020) 136 (Supplement 1): 46–48.

https://doi.org/10.1182/blood-2020-139337

Published: 2020

Journal Articles

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High Dose Melphalan and Autologous Stem Cell Transplantation

Ljupco Veskovski, MD, Per-Ola Andersson, MD PhD, Ingemar Turesson, MD PhD, Daniel Malmodin, PhD, Anders Pedersen, PhD, Ulf-Henrik Mellqvist, MD PhD

Blood (2019) 134 (Supplement_1): 1771.

https://doi.org/10.1182/blood-2019-121961

Published: 2019

Journal Articles

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Sara Bringhen, Peter M. Voorhees, MD, Torben Plesner, MD DSc, Ulf-Henrik Mellqvist, MD PhD, Brandi Reeves, MD, Pieter Sonneveld, Catriona Byrne, RN, Eva Nordström, MSc, Johan Harmenberg, MD PhD, Jakob Obermüller, MSc, Paul G. Richardson, MD

Blood (2019) 134 (Supplement_1): 1839.

https://doi.org/10.1182/blood-2019-124828

Published: 2019

Journal Articles

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Susanne Bram Ednersson, MD, Mimmie Stern, MD, Henrik Fagman, Gunilla Enblad, Ulf-Henrik Mellqvist, MD PhD, Herman Nilsson-Ehle, MD PhD, Sverker Hasselblom, Per-Ola Andersson, MD PhD

Blood (2019) 134 (Supplement_1): 3967.

https://doi.org/10.1182/blood-2019-126387

Published: 2019

Journal Articles

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

Shaji Kumar, MD, Meletios A Dimopoulos, Efstathios Kastritis, MD, Evangelos Terpos, Hareth Nahi, Hartmut Goldschmidt, MD, Jens Hillengass, MD, Xavier Leleu, Meral Beksac, MD, Melissa Alsina, MD, Albert Oriol, MD, Michele Cavo, MD, Enrique M. Ocio, MD PhD, Maria Victoria Mateos, Elizabeth K. O'Donnell, MD, Ravi Vij, MD MBA, Henk M. Lokhorst, MD PhD, Niels W.C.J. van de Donk, MD PhD, Chang-Ki Min, Tomer Mark, MD MSc, Ingemar Turesson, MD, PhD, Markus Hansson, MD, Heinz Ludwig, Sundar Jagannath, MD, Michel Delforge, MD PhD, Charalampia Kyriakou, MD PhD, Parameswaran Hari, MBBS, MD MRCP, Ulf-Henrik Mellqvist, MD PhD, Saad Z Usmani, MD FACP, Dominik Dytfeld, MD PhD, Ashraf Z Badros, MD, Philippe Moreau, Kihyun Kim, MD PhD, Paula Rodriguez Otero, MD, Jae Hoon Lee, MD, Chaim Shustik, MD, Daniel Waller, PhD, Wee Joo Chng, MD PhD, Shuji Ozaki, MD PhD, Je-Jung Lee, Javier de la Rubia, Hyeon Seok Eom, MD PhD, Laura Rosinol, MD PhD, Juan José Lahuerta, MD PhD, Anna Sureda, MD PhD, Jin Seok Kim, MD PhD, Brian G.M. Durie, MD

Blood (2016) 128 (22): 4414.

https://doi.org/10.1182/blood.V128.22.4414.4414

Published: 2016

Journal Articles

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Johan Lund, MD, Sigrid Karstorp, MD, Evren Alici, MD PhD, Astrid Gruber, MD PhD, Birgitta Lauri, MD, Cecilie Blimark, MD PhD, Agneta Swedin, MD PhD, Markus Hansson, MD PhD, Karin Forsberg, MD, Lucia Ahlberg, MD, Carlsson Conny, MD, Anders Waage, MD PhD, Peter Gimsing, Annette Juul Vangsted, MD PhD, Ulf Christian Frølund, MD, Mats Hardling, Ulf-Henrik Mellqvist, MD PhD, Hareth Nahi

Blood (2015) 126 (23): 3047.

https://doi.org/10.1182/blood.V126.23.3047.3047

Published: 2015

Journal Articles

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Peter M. Voorhees, MD, Valeria Magarotto, MD, Pieter Sonneveld, MD PhD, Torben Plesner, MD, Ulf-Henrik Mellqvist, MD PhD, Claudia E. Paba-Prada, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Antonio Palumbo, MD, Paul Richardson, MD

Blood (2015) 126 (23): 3029.

https://doi.org/10.1182/blood.V126.23.3029.3029

Published: 2015

Journal Articles

Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

Claudia Paba-Prada, MD, Antonio Palumbo, MD, Ulf-Henrik Mellqvist, MD PhD, Peter M Voorhees, MD, Torben Plesner, MD, Pieter Sonneveld, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Paul G. Richardson

Blood (2014) 124 (21): 2123.

https://doi.org/10.1182/blood.V124.21.2123.2123

Published: 2014

Journal Articles

Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis

Stefan O Schonland, MD, Ute Hegenbart, MD, Simona Iacobelli, Ph. D., Jennifer Hoek, M Rovira, Guustaaf van Imhoff, G Bandini, Ulf-Henrik Mellqvist, MD, PhD, Veronique Leblond, MD, Kristina Carlson, Samo Zver, MD, Ph.D, Didier Blaise, MD, Emilio Paolo Alessandrino, MD, Laurent Garderet, Nicolaus Kröger, MD

Blood (2013) 122 (21): 417.

https://doi.org/10.1182/blood.V122.21.417.417

Published: 2013

Journal Articles

Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.

Hareth Nahi, Johan Liwing, Anders Aldrin, Johan Andreasson, Cecilie Blimark, MD, Kristina Carlson, Jon Enestig, Max Flogegård, Karin Forsberg, Astrid Gruber, MD, PhD, Peter Johansson, MD, PhD, Helene Kviele, Birgitta Lauri, Ulf-Henrik Mellqvist, MD, PhD, Per Näsman, Agneta Swedin, Magnus Svensson, Katarina Uttervall, MD, PhD-student, Johan Aschan, MD, PhD

Blood (2012) 120 (21): 2970.

https://doi.org/10.1182/blood.V120.21.2970.2970

Published: 2012

Journal Articles

Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients

Cecilie Blimark, M.D., Ulf-Henrik Mellqvist, MD, PhD, Ola Landgren, M.D., Ph.D., Magnus Björkholm, MD, PhD, Malin L Hultcrantz, MD, Christian Kjellander, MD, Ingemar Turesson, MD, PhD, Erik Holmberg, PhD, Sigurdur Y Kristinsson, M.D., Ph.D.

Blood (2012) 120 (21): 945.

https://doi.org/10.1182/blood.V120.21.945.945

Published: 2012

Journal Articles

A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support

Peter Gimsing, MD, DMSci, Assoc. Prof., Oyvind Hjertner, Niels Abildgaard, Niels Frost Andersen, Tobias Gedde Dahl, Henrik Gregersen, MD, Ulf-Henrik Mellqvist, MD, PhD, Olle Linder, Roald Lindas, Niels-Aage Tøfner Clausen, Stig Lenhoff

Blood (2011) 118 (21): 3073.

https://doi.org/10.1182/blood.V118.21.3073.3073

Published: 2011

Journal Articles

Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study

Sigurdur Y. Kristinsson, MD, PhD, Tang Min, PhD, Ruth Pfeiffer, PhD, Magnus Björkholm, MD, PhD, Lynn Goldin, PhD, Cecilie Blimark, MD, Ulf-Henrik Mellqvist, MD, PhD, Anders Wahlin, MD, PhD, Ingemar Turesson, MD, PhD, Ola Landgren, MD, PhD

Blood (2010) 116 (21): 4053.

https://doi.org/10.1182/blood.V116.21.4053.4053

Published: 2010

Journal Articles

Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.

Sigurdur Y Kristinsson, M.D., Ph.D., Ruth Pfeiffer, PhD, Magnus Bjorkholm, MD, PhD, Lynn R Goldin, PhD, Sam Schulman, MD, PhD, Cecilie Blimark, MD, Ulf-Henrik Mellqvist, MD, PhD, Anders Wahlin, MD, PhD, Ingemar Turesson, MD, PhD, Ola Landgren, M.D., Ph.D.

Blood (2009) 114 (22): 1872.

https://doi.org/10.1182/blood.V114.22.1872.1872

Published: 2009

Journal Articles

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.

Blood (2009) 114 (22): 530.

https://doi.org/10.1182/blood.V114.22.530.530

Published: 2009

Journal Articles

Familial Aggregation of Multiple Myeloma and Its Precursor Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study in Sweden.

Sigurdur Y Kristinsson, M.D., Magnus Bjorkholm, MD, PhD, Lynn R. Goldin, Ph.D., Cecilie Blimark, M.D., Ulf-Henrik Mellqvist, MD, PhD, Anders Wahlin, MD, PhD, Ingemar Turesson, MD, PhD, Ola Landgren, M.D., Ph.D.

Blood (2008) 112 (11): 1678.

https://doi.org/10.1182/blood.V112.11.1678.1678

Published: 2008

Journal Articles

Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.

Ola Landgren, MD, PhD, Sigurdur Y. Kristinsson, MD, Lynn R. Goldin, PhD, Neil E. Caporaso, MD, Cecilie Blimark, MD, Ulf-Henrik Mellqvist, MD, PhD, Anders Wahlin, MD, PhD, Magnus Bjorkholm, MD, PhD, Ingemar Turesson, MD, PhD

Blood (2007) 110 (11): 660.

https://doi.org/10.1182/blood.V110.11.660.660

Published: 2007

Journal Articles

Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial.

Ulf-Henrik Mellqvist, MD, PhD, Stig Lenhoff, MD, PhD, Martin Hjorth, MD, PhD, Erik Holmberg, PhD, Gunnar Juliusson, MD, PhD, Jon Magnus Tangen, MD, PhD, Jan Westin, MD, PhD, Hans Johnsen, MD, PhD

Blood (2006) 108 (11): 793.

https://doi.org/10.1182/blood.V108.11.793.793

Published: 2006

NARROW

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95)

Serum Metabolomic Profiling Correlated with ISS and Clinical Outcome for Multiple Myeloma Patients Treated with High Dose Melphalan and Autologous Stem Cell Transplantation

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Quantitative Proteomics in Diffuse Large B-Cell Lymphoma Patients Reveal Novel Overexpressed Proteins and Potentially Druggable Targets in the ABC Subtype

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

Center Experience and Calendar Year Of Transplantation Strongly Influence Short Term Survival After Autologous Peripheral Blood Transplantation In 1315 Patients With Light Chain Amyloidosis: An EBMT Analysis

Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population.

Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients

A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support

Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study

Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.

Familial Aggregation of Multiple Myeloma and Its Precursor Monoclonal Gammopathy of Undetermined Significance (MGUS): A Population-Based Study in Sweden.

Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.

Dexamethasone and Cyclophosphamide: More Convenient and as Effective as VAD before High-Dose Melphalan and Autologous Transplantation in Newly Diagnosed Multiple Myeloma. Results of a Randomized NMSG Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only